Výsledky vyhledávání - "Manuel, Afable"

Pegilodecakin as monotherapy or in combination with anti‐PD ‐1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study

Autor: Kyriakos P. Papadopoulos, David Ferry, Manuel Afable, Nizar M. Tannir, Alexandra Drakaki, Annie Hung, Jong Seok Kim, Johanna C. Bendell, Raid Aljumaily, Deborah J. Wong, Aung Naing

Publikováno v: International Journal of Cancer. 149:403-408

Interleukin (IL)-10 has anti-inflammatory and CD8+ T-cell-stimulating properties. Pegilodecakin (pegylated recombinant human IL-10) induces intratumoral antigen-specific CD8 + T-cells and upregulates IFNγ and major histocompatibility complexes (MHC)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b45efde30c4fd062777672d1730f62dc
https://doi.org/10.1002/ijc.33556

Zobrazit plný text záznamu

Cost-minimization analysis of biweekly dosing of cetuximab and FOLFIRI compared with panitumumab and FOLFOX for first-line treatment of patients with KRAS wild-type metastatic colorectal cancer in the United States

Autor: Devarshi Bhattacharyya, Taha Khan, Harsheen Sethi, Wambui Gathirua-Mwangi, Manuel Afable

Publikováno v: Journal of medical economics. 24(1)

To compare the cost of biweekly regimens of first-line (1L) treatments of cetuximab-folinic acid, fluorouracil, and irinotecan (FOLFIRI)Cost-minimization analysis (CMA) was performed to estimate per-patient cost differences of cetuximab-FOLFIRIFor th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15716b8f3efdf0a8bcd8a038f18c0119
https://pubmed.ncbi.nlm.nih.gov/34529522

Zobrazit plný text záznamu

Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study

Autor: Nizar M, Tannir, Kyriakos P, Papadopoulos, Deborah J, Wong, Raid, Aljumaily, Annie, Hung, Manuel, Afable, Jong Seok, Kim, David, Ferry, Alexandra, Drakaki, Johanna, Bendell, Aung, Naing

Publikováno v: International Journal of Cancer

Interleukin (IL)‐10 has anti‐inflammatory and CD8+ T‐cell‐stimulating properties. Pegilodecakin (pegylated recombinant human IL‐10) induces intratumoral antigen‐specific CD8 + T‐cells and upregulates IFNγ and major histocompatibility c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::74904cdf002dabe4b74a066ae9143aa5
https://pubmed.ncbi.nlm.nih.gov/33709428

Zobrazit plný text záznamu

Akademický článek

A case of mistaken identity: When lupus masquerades as primary myelofibrosis

Autor: Edy Hasrouni, Heesun J Rogers, Ali Tabarroki, Valeria Visconte, Fabiola Traina, Manuel Afable, Mikkael A Sekeres, Jaroslaw P Maciejewski, Ramon V Tiu

Publikováno v: SAGE Open Medical Case Reports, Vol 1 (2013)

Introduction: Autoimmune myelofibrosis is an uncommon hematologic disease characterized by anemia, bone marrow myelofibrosis, and an autoimmune feature. Myelofibrosis is often associated with other conditions, including infections, nutritional/endocr

Externí odkaz: https://doaj.org/article/746921e3e39c4c88b40350deca79f8c4

Zobrazit plný text záznamu

Akademický článek

Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia

Autor: Sarah Abu Kar, Anna Jankowska, Hideki Makishima, Valeria Visconte, Andres Jerez, Yuka Sugimoto, Hideki Muramatsu, Fabiola Traina, Manuel Afable, Kathryn Guinta, Ramon V. Tiu, Bartlomiej Przychodzen, Hirotoshi Sakaguchi, Seiji Kojima, Mikkael A. Sekeres, Alan F. List, Michael A. McDevitt, Jaroslaw P. Maciejewski

Publikováno v: Haematologica, Vol 98, Iss 1 (2013)

Chronic myelomonocytic leukemia is a heterogeneous disease with multifactorial molecular pathogenesis. Various recurrent somatic mutations have been detected alone or in combination in chronic myelomonocytic leukemia. Recently, recurrent mutations in

Externí odkaz: https://doaj.org/article/82c33b14cab844798bb1eb8b8b6be080

Zobrazit plný text záznamu

Akademický článek

Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia

Autor: Sanjay R. Mohan, Michael J. Clemente, Manuel Afable, Heather N. Cazzolli, Nelli Bejanyan, Marcin W. Wlodarski, Alan E. Lichtin, Jaroslaw P. Maciejewski

Publikováno v: Haematologica, Vol 94, Iss 10 (2009)

Background T-cell large granular lymphocytic leukemia is a clonal proliferation of cytotoxic T-lymphocytes which often results in severe cytopenia. Current treatment options favor chronic immunosuppression. Alemtuzumab, a humanized monoclonal antibod

Externí odkaz: https://doaj.org/article/be73037de0ea4e4480e6aecfe4df7a2b

Zobrazit plný text záznamu

A retrospective analysis of real-world time on treatment and overall survival in patients with metastatic colorectal cancer receiving cetuximab in third line

Autor: Yixun Wu, Wambui Gathirua-Mwangi, Taha Khan, Manuel Afable, Tony Yang

Publikováno v: Journal of Clinical Oncology. 39:e15575-e15575

e15575 Background: Colorectal cancer (CRC) is the 3rd leading cause of cancer-related deaths in the US. Anti-epidermal growth factor receptor agents improve outcomes of patients with metastatic CRC (mCRC) and are used in multiple lines of therapy. Ho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9287fe5fac0f0af94e6476d3133da3de
https://doi.org/10.1200/jco.2021.39.15_suppl.e15575

Zobrazit plný text záznamu

Real-world time on treatment and overall survival in patients with metastatic colorectal cancer receiving cetuximab in second line after failing irinotecan or oxaliplatin-based regimens

Autor: Taha Khan, Yixun Wu, Tony Yang, Manuel Afable, Wambui Gathirua-Mwangi

Publikováno v: Journal of Clinical Oncology. 39:e15568-e15568

e15568 Background: Anti-epidermal growth factor receptor agents are increasingly used in later lines of therapy for the treatment of metastatic colorectal cancer (mCRC). However, the real-world time on treatment (TOT) and overall survival (OS) of pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b97a226c108d427dafbf6f34a0f36a1e
https://doi.org/10.1200/jco.2021.39.15_suppl.e15568

Zobrazit plný text záznamu

Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma (RCC): Updated results from phase I/Ib IVY study

Autor: Manuel Afable, David Ferry, Alexandra Drakaki, Kyriakos P. Papadopoulos, Annie Hung, Johanna C. Bendell, Jong Seok Kim, Nizar M. Tannir, Raid Aljumaily, Deborah J.L. Wong, Aung Naing

Publikováno v: Journal of Clinical Oncology. 38:679-679

679 Background: Pegilodecakin (PEG), a pegylated recombinant human interleukin-10, has demonstrated clinical benefit and manageable toxicity in advanced RCC (Naing et al. 2016 JCO, Naing et al. 2019 Lancet Oncol). As part of the multi-arm (arm A to J

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ab28e4a22cfe73ec75f10d12d1a9ddea
https://doi.org/10.1200/jco.2020.38.6_suppl.679

Zobrazit plný text záznamu

Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30+ Lymphoma Patients Who Received Multiple Prior Lines of Treatment

Autor: Paolo Caimi, Basem M. William, Richard E. Champlin, Manuel Afable, Stanton L. Gerson, Chitra Hosing, Issa F. Khouri, Uday R. Popat, Brenda W. Cooper, Paolo Anderlini, Yago Nieto, Marcos de Lima, Hillard M. Lazarus

Publikováno v: Biology of Blood and Marrow Transplantation. 21:1529-1531

Brentuximab vedotin (BV), an antibody-drug conjugate that targets CD30, induces high response rates in CD30(+) lymphoid malignancies. It is unknown if BV use affects procurement of autologous CD34(+) stem cells and hematopoietic engraftment after aut

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34ab1a7f11742f227a9795cafafaa652
https://doi.org/10.1016/j.bbmt.2015.04.022

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání